Results 121 to 130 of about 3,132 (216)

Cross-Sectional Survey of Real-World Physician Prescribing Practices for Anti-VEGF Agents in the Treatment of Neovascular Age-Related Macular Degeneration and Associated Patient Burden in the United States

Clinical Ophthalmology
Shilpa Gulati,1,2 Emily Coak,3 Daniel Mascia,3 Katherine Li,3 Stella Ko,4 Nicole Gidaya Bonine4 1New England Retina Consultants, Springfield, MA, USA; 2Massachusetts Chan Medical School, University of Massachusetts, Worcester, MA, USA; 3Adelphi Real ...
Gulati S, Coak E, Mascia D, Li K, Ko S, Bonine NG   +5 more
doaj  

Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea

Scientific Reports
To analyze visual and anatomic outcomes of faricimab injection in neovascular age-related macular degeneration (nAMD) in a real-world setting in Korea. We collected data from nAMD patients who received faricimab injection from 2024 to 2025.
Doh Hoon Chung, Donghyun Jee, Young Jung Roh, Ho Ra, Mee Yon Lee, Jae Yon Won, Jeong Ah Shin, Suk Hoon Jung, Young-Hoon Park   +8 more
doaj   +1 more source

Faricimab efficacy in a poorly responsive case of Polypoidal Choroidal Vasculopathy (PCV): A case report

Purpose: To evaluate anatomical and functional outcomes of Faricimab therapy on a case of polypoidal choroidal vasculopathy (PCV) refractory to previous treatments. Major findings: A 56-year-old patient with PCV presenting with a large pigment epithelial
Savastano M. C., Rizzo S.
core   +1 more source

1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration

Eye
I. Janmohamed, A. Mushtaq, J. Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, A. Ata, H. Monye, Zakariya A Jarrar, S. Hannan, L. Membrey   +9 more
semanticscholar   +1 more source

COMPARATIVE CLINICAL OUTCOMES OF FARICIMAB VERSUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: A FOCUSED REVIEW

This manuscript presents a focused narrative review with systematic literature identification of comparative evidence on faricimab versus aflibercept in adults with diabetic macular edema. The review prioritized randomized phase III evidence and selected
Karolina Klusek, Nadzieja Krasucka, Magdalena Kijowska, Michał Batory, Aleksandra Zynkowska, Maria Kiełbus, Aleksandra Magdalena Skrzyniarz, Julia Oziębło, Karol Kraska, Jakub Jakubowski   +9 more
core   +1 more source

Faricimab in the Treatment of Retinal Disease: A Narrative Review. [PDF]

Cureus
Zeaiter M, Jaber H, Gharbi K, Fernandes SMB, Mchaik J, Ahmed M, Hassan A, Hammoud AA.   +7 more
europepmc   +1 more source

Refractory Perifoveal Exudative Vascular Anomalous Complex (PEVAC)- Early Positive Response to Faricimab Therapy

Purpose: To describe a case of refractory unilateral PEVAC macular edema initially treated with intravitreal faricimab injections. Methods:
Eduardo Cunha Souza
core   +1 more source

Visual and Anatomic Outcomes in nAMD Patients With Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Purpose : Faricimab was FDA-approved for nAMD in Jan 2022. Current agents provide benefit to patients but demonstrate declines in visual acuity as treatments continue.
Wolfe, Jeremy, Aziz, Aamir Abdul, Bhandari, Ramanath, Chang, Emmanuel, Abbey, Ashkan Michael, Mojumder, Ohidul, Khan, Hannah, Banda, Himanshu K, Avery, Robert L, Barakat, Mark Rami   +9 more
core   +2 more sources

The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study

Purpose : Faricimab was FDA-approved for diabetic macular edema (DME) in January 2022. This multi-center, prospective study evaluates the safety and efficacy of faricimab in real-world patients diagnosed with DME.
Corradetti, Giulia, Graff, Jordan M, Nielsen, Jared, Wolfe, Jeremy, Khan, Huma, Gahn, Greggory, Aziz, Aamir A, Danzig, Carl J, Khan, Hannah, Barakat, Mark Rami   +9 more
core   +1 more source

Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study. [PDF]

Pharmaceuticals (Basel)
Panos GD.
europepmc   +1 more source